Barclays Has Lowered Expectations for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN - Free Report) had its price target lowered by Barclays from $58.00 to $56.00 in a report published on Friday morning, MarketBeat.com reports. The brokerage currently has an equal weight rating on the stock.

A number of other brokerages have also weighed in on LIVN. Stifel Nicolaus decreased their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Mizuho reduced their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC lowered their price target on LivaNova from $75.00 to $64.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group decreased their target price on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $61.17.

Remove Ads

LivaNova Trading Up 5.5 %

NASDAQ LIVN traded up $2.04 during trading hours on Friday, hitting $39.06. 1,320,494 shares of the company's stock were exchanged, compared to its average volume of 635,789. The business's 50 day moving average is $46.61 and its 200-day moving average is $49.30. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a 12-month low of $36.85 and a 12-month high of $64.47. The firm has a market capitalization of $2.12 billion, a P/E ratio of 93.00 and a beta of 1.10.

Insider Activity

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.27% of the company's stock.

Hedge Funds Weigh In On LivaNova

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its stake in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after buying an additional 219 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of LivaNova by 1.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company's stock valued at $780,000 after acquiring an additional 289 shares during the last quarter. Atria Investments Inc raised its position in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company's stock valued at $297,000 after acquiring an additional 331 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in LivaNova by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock worth $328,000 after purchasing an additional 425 shares during the last quarter. Finally, Xponance Inc. boosted its holdings in LivaNova by 6.1% in the fourth quarter. Xponance Inc. now owns 7,762 shares of the company's stock worth $359,000 after purchasing an additional 445 shares during the period. Institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.